Resumen
Antibióticos para el tratamiento de la COVID-19
Maria Popp1, Miriam Stegemann2, Manuel Riemer1, Maria-Inti Metzendorf3, Carolina S. Romero4, Agata Mikolajewska2, Peter Kranke1, Patrick Meybohm1, Nicole Skoetz5, Stephanie Weibel1
Filiación de los autores
1Department of Anaesthesiology, Intensive Care, Emergency and Pain Medicine, University Hospital Wuerzburg, Wuerzburg, Alemania. 2Department of Infectious Diseases and Respiratory Medicine, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Alemania. 3Cochrane Metabolic and Endocrine Disorders Group, Institute of General Practice, Medical Faculty of the Heinrich-Heine-University Düsseldorf, Düsseldorf, Alemania. 4Department of Anaesthesiology, Intensive Care, Emergency and Pain Medicine, General University Hospital Valencia, Valencia, España. 5Cochrane Cancer, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Alemania.
DOI
Cita
Popp M, Miriam Stegemann M, Riemer M, Metzendorf MI, Romero CS, Mikolajewska A, et al. Antibióticos para el tratamiento de la COVID-19. Emergencias. 2023;35:378-80
